ArticleClinical immunology (Orlando, Fla.)2017
NK cells are biologic and biochemical targets of 6-mercaptopurine in Crohn's disease patients.
Article in Clinical immunology (Orlando, Fla.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Targeting cell death in Crohn's disease: from mechanisms to medicines.Cell death discovery · 2026Review
- Identification of a Novel Activated NK-Associated Gene Score Associated with Diagnosis and Biological Therapy Response in Ulcerative Colitis.Digestion · 2025Article
- Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment.Frontiers in cellular and infection microbiology · 2025Review
- WNT2B high‑expressed fibroblasts induce the fibrosis of IBD by promoting NK cells secreting IL-33.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy.Arthritis research & therapy · 2024Article
- Role of Rho GTPases in inflammatory bowel disease.Cell death discovery · 2023Review
- Inflammatory Bowel Disease: A Review of Pre-Clinical Murine Models of Human Disease.International journal of molecular sciences · 2022Review
- Immune Cell Landscaping Reveals Distinct Immune Signatures of Inflammatory Bowel Disease.Frontiers in immunology · 2022Article
- Effects of metabolic cancer therapy on tumor microenvironment.Frontiers in oncology · 2022Review
- Dysregulation of Metabolic Pathways in Circulating Natural Killer Cells Isolated from Inflammatory Bowel Disease Patients.Journal of Crohn's & colitis · 2021Article
- Review
- The Role of Immune Cells and Cytokines in Intestinal Wound Healing.International journal of molecular sciences · 2019Review
- Mosaic Tetrasomy 9p Associated With Inflammatory Bowel Disease.Journal of Crohn's & colitis · 2019Article
- Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential.Oncotarget · 2019Article
- Modulatory Effects of Pregnancy on Inflammatory Bowel Disease.Clinical and translational gastroenterology · 2019Review
- Human Gut-Associated Natural Killer Cells in Health and Disease.Frontiers in immunology · 2019Review
- Critical Roles of Balanced Innate Lymphoid Cell Subsets in Intestinal Homeostasis, Chronic Inflammation, and Cancer.Journal of immunology research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
NK cells, which contribute to immune defense against certain viral infections and neoplasia, are emerging as modifiers of chronic immunologic diseases including transplant rejection and autoimmune diseases. Immunobiology and genetic studies have implicated NK cells as a modifier of Crohn's disease, a condition often treated with thiopurine agents such as 6-mercaptopurine (6-MP). Here, we demonstrate that thiopurines mediate NK cell apoptosis via a caspase 3 and 9 inclusive pathway, and that this process is triggered by thiopurine-mediated inhibition of Rac1. We also show that CD patients in clinical remission maintained on 6-MP have decreased NK cell Rac1 activity, and decreased NK cell numbers in their intestinal biopsies. These observations suggest that thiopurine targeting of NK cells may be a previously unappreciated therapeutic action of these agents in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.